Recent Quotes (30 days)

You have no recent quotes
chg | %

STAAR Surgical Company  

(Public, NASDAQ:STAA)   Watch this stock  
Find more results for STAA
16.20
+0.75 (4.85%)
Real-time:   2:29PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.25 - 16.55
52 week 8.95 - 16.55
Open 15.60
Vol / Avg. 371,276.00/136,181.00
Mkt cap 666.86M
P/E     -
Div/yield     -
EPS -0.05
Shares 41.16M
Beta 1.09
Inst. own 78%
Nov 16, 2017
STAAR Surgical Co Investor and Analyst Day - Webcast
Nov 8, 2017
Q3 2017 STAAR Surgical Co Earnings Call - Webcast
Nov 8, 2017
Q3 2017 STAAR Surgical Co Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 5.00% -14.71%
Operating margin 4.44% -15.35%
EBITD margin - -11.80%
Return on average assets 6.90% -18.89%
Return on average equity 11.92% -31.61%
Employees 336 -
CDP Score - -

Address

1911 Walker Ave
MONROVIA, CA 91016
United States - Map
+1-626-3037902 (Phone)
+1-626-3032962 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). As of December 30, 2016, it sold its products in more than 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.

Officers and directors

Caren L. Mason President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Deborah J. Andrews Chief Financial Officer, Vice President
Age: 59
Bio & Compensation  - Reuters
Hans-Martin Blickensdoerfer Senior Vice President - Commercial Operations for Europe, Middle East, Africa, Latin America and China.
Age: 52
Bio & Compensation  - Reuters
James E. Francese Senior Vice President of North American and APAC
Age: 51
Bio & Compensation  - Reuters
Keith Holliday Ph.D. Chief Technology Officer, Vice President
Age: 54
Bio & Compensation  - Reuters
Surindra Mann Vice President - Global Financial Planning and Analysis
Bio & Compensation  - Reuters
William Walter Goodmen Vice President - Global Human Resources
Age: 60
Bio & Compensation  - Reuters
Jon K. Hayashida Vice President - Global Clinical and Medical Affairs
Bio & Compensation  - Reuters
Philippe Subrin Vice President-ICL Manufacturing
Age: 51
Bio & Compensation  - Reuters
Samuel J. Gesten Vice President - Business Development, Chief Legal Officer and Secretary
Age: 55
Bio & Compensation  - Reuters